ASH 2019: Acute Myeloid Leukemia
Filter Results
A New Strategy for Selinexor in Newly Diagnosed, Elderly Patients With AML
Acute myeloid leukemia (AML) is the most frequently encountered acute leukemia in adults, with a projection of more than 21,000 new diagnoses for this year in the US.
Socioeconomic Disparities Affect Survival of Children in AML Clinical Trials
Socioeconomic status has been identified for the first time as a key contributor to disparities among children with acute myeloid leukemia (AML) who were enrolled in clinical trials.
Primary Induction Failure & Early Relapsed Acute Myeloid Leukemia
Updated results from a phase I/II dose-expansion study of flotetuzumab, an investigational, bispecific CD123 x CD3 DART molecule in patients with primary induction failure and early relapsed acute myeloid leukemia (AML) were presented in an oral session at the 2019 ASH Annual Meeting (Abstract 733).
Positive Data of APR-246 & Azacitidine in Patients with TP53 MDS & AML
Lead investigators from the U.S. and French phase Ib/II clinical trials of APR-246 and azacitidine (AZA) in patients with TP53-mutant myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), presented positive data at the 2019 ASH Annual Meeting.
Pediatric AML Management After Chemotherapy: Outpatient vs. Inpatient Care
Do pediatric patients with acute myeloid leukemia (AML) have to stay in the hospital after undergoing chemotherapy? Or, is it safe to send them home?
Driver Mutations Identified for AML & Myelodysplastic Syndrome
The first comprehensive analysis combining full genomic sequencing and gene expression profiles of more than 1,300 patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) has identified prognostic constellations of driver mutations in these myeloid neoplasms.
Maintenance Therapy Markedly Improves Overall Survival in AML Patients in Remission
An investigational oral form of azacitidine therapy significantly improved overall survival (OS) in older patients with newly diagnosed acute myeloid leukemia (AML) who were in remission following standard induction chemotherapy, with or without consolidation therapy, according to results of a new study (Abstract LBA-3).
Disparities in Kidney Function Should Not Exclude Minorities From AML Clinical Trials
African American patients with acute myeloid leukemia (AML) may have more abnormal kidney function than white patients, but this does not necessarily lead to any difference in overall survival, according to a new study (Abstract 381).
First-in-Human Study of Fc-Optimized Antibody FLYSYN for Acute Myeloid Leukemia
Interim results of the first-in-human clinical study of FLYSYN, a novel Fc-optimized antibody, for the treatment of acute myeloid leukemia (AML), were presented at 2019 ASH Annual Meeting (Abstract 3928).